Other Events in the Series:

Advancing Safe & Durable 2nd Generation Cytokine Therapies into the Clinic

With a plethora of cytokine-based modalities and targets storming across biopharma, the complexities and interactions of cytokines involved in the immune system is an exciting opportunity for all. From understanding biology to discovering and combining novel therapeutic technologies to drive clinical success in oncology and beyond.

Predominantly focusing on harnessing cytokine-based therapeutic modalities for cancer indications, the 3rd Annual Cytokine-Based Drug Development Summit’s comprehensive 4-day agenda will highlight the exciting new progress in engineered interleukins (IL-2, IL-12 and IL-15), in addition to covering the industry’s most pressing translational challenges across other cytokines (IFN, TGF-β, IL-7 and more), such as working with preclinical models, optimizing cytokine targeting and delivery, discussing half-life, dosing and therapeutic window challenges, defining relevant clinical endpoints and overcoming toxicity with novel engineering technology.

Join 100+ of your industry-based peers to learn, share and discuss the industry’s key challenges in-person this July. With 4 content packed days covering the latest results coming out of the clinic and addressing the shortfalls of these therapies, this is not one to miss!

New Features for 2022

Our Pre and Post Conference Workshop Days are specifically dedicated to addressing other hot topics in depth, such as cytokine-armed oncolytic viruses, approaching combination therapies, and developing cytokine-based therapies for indications beyond oncology, including cytokines in COVID, inflammatory and autoimmune diseases.

World-Class Speaker Faculty Includes

John Cini

Chief Scientific Officer & Co-Founder

Sonnet BioTherapeutics Inc.

Laszlo Radvanyi

Chairman Scientific Advisory Board

Proviva Therapeutics

Omid Veiseh


Avenge Bio

Paula Fraenkel

Executive Director & Global Project Lead


Richard Klemke


Cytonus Therapeutics, Inc

Other Events in the Series: